Sionna Therapeutics vs Neuralink
Side-by-side comparison of AI visibility scores, market position, and capabilities
Sionna Therapeutics is developing next-generation small molecule CFTR modulators targeting full restoration of CFTR protein function in cystic fibrosis patients; raised $170M+ total;
About
Sionna Therapeutics is a clinical-stage biopharmaceutical company founded in 2020 and headquartered in Lexington, Massachusetts. The company was founded with a focus on discovering and developing next-generation treatments for cystic fibrosis (CF) — a life-threatening genetic disease caused by mutations in the CFTR (cystic fibrosis transmembrane conductance regulator) gene that impair the protein's ability to regulate fluid transport in the lungs, digestive tract, and other organs. While Vertex Pharmaceuticals' Trikafta has transformed CF treatment for patients with the most common mutation (F508del), Sionna aims to develop modulators that more fully restore CFTR function and address patient segments not adequately covered by existing drugs.
Pioneer of implantable BCIs with 12+ active human patients as of Sep 2025; raised $650M Series E in Apr 2026 led by ARK Invest and Sequoia at a ~$14.9B valuation; mass production underway.
About
Neuralink is a neurotechnology company founded in 2016 by Elon Musk and a team of neuroscientists and engineers, developing implantable brain-computer interface devices that enable individuals with paralysis to control digital devices directly with their thoughts. The company's first commercial product, the N1 implant, is a coin-sized device containing 1,024 electrodes that is surgically placed in the motor cortex. As of September 2025, twelve patients worldwide had received the N1 implant and were actively using it to control computers, smartphones, and robotic arms with neural signals alone.
Key Details
Also Compare
Track AI Visibility in Real Time
Monitor how your brand performs across ChatGPT, Gemini, Perplexity, Claude, and Grok daily.